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Kinetic analysis of the accumulation
of a half-sandwich organo-osmium pro-drug
in cancer cells†
Annabelle Ballesta, *ab Fre´de´rique Billy, a James P. C. Coverdale, c
Ji-Inn Song,c Carlos Sanchez-Cano, c Isolda Romero-Canelo´n *cd and
Peter J. Sadler *c
The organo-osmium half-sandwich complex [(Z6-p-cymene)Os(Ph-azopyridine-NMe2)I]
+ (FY26) exhibits
potent antiproliferative activity towards cancer cells and is active in vivo. The complex is relatively inert, but
rapidly activated in cells by displacement of coordinated iodide. Here, we study time-dependent accumulation
of FY26 in A2780 human ovarian cancer cells at various temperatures in comparison with the chlorido
metabolite [(Z6-p-cymene)Os(Ph-azopyridine-NMe2)Cl]
+ (FY25). Mathematical models described the time
evolution of FY26 and FY25 intracellular and extracellular concentrations taking into account both cellular
transport (influx and eﬄux) and the intracellular conversion of FY26 to FY25. Uptake of iodide complex FY26
at 37 1C was 17 faster than that of chloride complex FY25, and eﬄux 1.4 faster. Osmium accumulation
decreased markedly after 24 h of exposure. Modelling revealed that this phenomenon could be explained by
complex-induced reduction of osmium uptake, rather than by a model involving enhanced osmium eﬄux.
The intracellular osmium concentration threshold above which reduction in drug uptake was triggered was
estimated as 20.8 mM (95% confidence interval [16.5, 30]). These studies provide important new insight into
the dynamics of transport of this organometallic anticancer drug candidate.
Significance to metallomics
Resistance and side-eﬀects of platinum compounds are current major clinical problems and so the development of alternative metal compounds is needed.
Here we studied the organo-osmium complex FY26, a potent prodrug which is active in vitro and in vivo and is not cross-resistant with platinum drugs. The
cellular transport and metabolism of FY26 were investigated in human ovarian cancer cells through combined mathematical and experimental tools. Such data
are likely to be important for furthering the clinical development of FY26. The presented interdisciplinary methodology guides the design of experiments, thus
decreasing the costs associated to drug development.
Introduction
Around half of all cancer chemotherapy treatments currently use
platinum compounds, including cisplatin, carboplatin and oxa-
liplatin, introduced over 30 years ago. Despite the success of such
therapies, resistance to platinum is now a clinical problem,
together with drug-induced side-eﬀects.1,2 Complexes of other
preciousmetals may provide anticancer drugs with newmechanisms
of action to overcome such resistance, and fewer side-eﬀects. Organo–
metallic complexes, and osmium(II) arene complexes in particular,
have recently shown promising results.3–7
In general, metallodrugs are pro-drugs which undergo ligand
exchange or redox reactions before they reach the target site. For
example, cisplatin contains square-planar 5d8 Pt(II) and is activated
in cells by hydrolysis (aquation), in which chlorido ligands are
substituted by water. The aqua adducts, and resulting positively-
charged complexes, are much more reactive towards target DNA.
Octahedral platinum(IV) anticancer complexes are even more
unreactive, as is common with low-spin 5d8 complexes, and are
activated in vivo by reduction to Pt(II). Such inertness allows some
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low-spin d6 complexes to reach their target sites intact and bind by
outer sphere interactions, e.g. between the ligands and amino acid
side-chains in an enzyme binding site, for example potent kinase
inhibitors of staurosporine conjugated to Ru(II) and Ir(III).8 How-
ever, the inertness of such metal ions is dependent not only on the
electronic configuration of the metal, but also on the nature of the
ligands to which it is bound.
Here we study the inert iodido complex [(Z6-p-cymene)OsII(N,N-
dimethyl-phenylazopyridine)I]+ (FY26) which is ca. 49 more active
than cisplatin, in a panel of over 800 cancer cell lines screened by the
Sanger Institute, and also active in vivo.9,10 FY26 is not cross-resistant
with cisplatin, nor the second generation Pt(II) drug oxaliplatin,
retaining potency in resistant/non-sensitive cell lines, which suggests
a diﬀerent mechanism of action.10–12 The complex appears to act as
a redox modulator, disrupting mitochondria and inducing genera-
tion of reactive oxygen species (ROS), especially superoxide, which
has been observed in both cancer cells and in vivo.10–12 Such a
mechanism exploits an inherent weakness in cancer cells, as their
malfunctioning mitochondria cannot cope with overproduction of
ROS. This likely contributes to the increased selectivity of FY26
towards cancer cells versus normal cells compared to cisplatin.13
Surprisingly, FY26 does not readily undergo hydrolysis in
the extracellular medium. However, we discovered by 131I
radiolabelling that FY26 is rapidly activated inside cancer cells
by displacement of its iodide ligand.14 Intriguingly, this activa-
tion appears to be mediated by attack of the intracellular
tripeptide glutathione (GSH) on the azo bond of FY26 in a
catalytic mechanism which weakens the Os–I bond.15 Under
intracellular cytoplasmic conditions where the chloride concen-
tration is ca. 25 mM, HPLC studies show that this reaction can
lead to the generation of the chlorido complex FY25.11 We have
detected the chlorido complex FY25 as a metabolite in liver
microsomes after reactions with FY26 (unpublished data).
The importance of pharmacodynamic (PD) and pharmacokinetic
(PK) studies in preclinical drug development based on mathema-
tical modelling has recently been emphasised.16 As a key part of
such studies, we have investigated the kinetics of the influx and
eﬄux of both the iodido organo-osmium prodrug FY26 and its
chlorido metabolite FY25 in human ovarian cancer cells. We have
constructed a mathematical model which describes the time evolu-
tion of each chemical species, taking into account both cellular
transport, and intracellular conversion of FY26 into FY25 (Fig. 1).
Experimental section
Ovarian cell line
A2780 human ovarian carcinoma cells were obtained from the
European Collection of Cell Cultures (ECACC) and grown in
Roswell Park Memorial Institute medium (RPMI-1640) supple-
mented with 10% of foetal calf serum, 1% of 2 mM glutamine
and 1% penicillin/streptomycin using a 5% CO2 humidified
atmosphere and passaged at approximately 70–80% confluence.
Drugs and reagents
FY25 and FY26 were synthesized and characterized with purities
495% according to reported methods.11 Osmium stock solution
standardization: stock solutions of FY25 and FY26 were freshly
prepared in RPMI-1640 cell culture medium using 5% DMSO
to aid solubilisation. An aliquot was taken and diluted using
3.6% nitric acid (containing thiourea (10 mM) and ascorbic acid
(100 mg L1) to stabilize Os in nitric acid solution).17 The
resulting solution was analysed using a PerkinElmer Optima
5300DV ICP-OES. Calibration standards for Os (50–700 ppb) were
freshly prepared in 3.6% nitric acid (containing 10 mM thiourea
and 100 mg L1 ascorbic acid).17 Data were acquired and pro-
cessed using WinLab32 for Windows.
Cellular osmium accumulation (without recovery time)
Briefly, 4  106 A2780 ovarian cancer cells were seeded on a Petri
dish. After 24 h of pre-incubation time in drug-free medium at
either 4 1C, 23 1C or 37 1C, the osmium complexes were added to
give final concentrations equal to their IC50 (1.8  0.1 mM and
0.15  0.01 mM for FY25 and FY26, respectively). Cells were
exposed to the Os(II) complexes with variable exposure time, but
without recovery time in drug-free medium. Cells were then
washed, treated with trypsin/EDTA and counted. Cell pellets
were collected and washed again with PBS. Each pellet was
digested overnight in 200 mL freshly-distilled concentrated nitric
acid (72%) at 353 K. Experiments were carried out in triplicate
and the standard deviations were calculated. Statistical signifi-
cances were determined using Welch’s unpaired t-test.
Cellular osmium accumulation (with recovery time)
These experiments were carried out as above, using fixed 24 h drug
exposure time and equipotent IC50 concentrations. After drug-
exposure, supernatants were removed, cells were washed with PBS
and fresh medium was added to each plate. Multiple recovery
times in drug free medium were allowed before collecting cell
pellets that were again processed as for the previous experiment.
Osmium cell pellet quantification
The resulting solutions after cell digestion were diluted using
doubly-distilled (MilliQ) water containing thiourea (10 mM) and
ascorbic acid (100 mg L1)17 to achieve a final working acid
concentration of 3.6% v/v HNO3. Osmium (
189Os) was quantified
using an Agilent 7500 series ICP-MS in no-gas mode with an
internal standard of 166Er (50 ppb). Calibration standards
(0.1–1000 ppb) were freshly prepared in 3.6% nitric acid supple-
mented with thiourea (10 mM) and ascorbic acid (100 mg L1) to
stabilize osmium in nitric acid solution.7,17 Osmium concentra-
tions were first expressed in ng per million cells using cell counts
from biological experiments. Experiments were carried out as
triplicates and standard deviations were calculated. Data were
acquired and processed using ICP-MS-TOP and Offline DataFig. 1 Structures of the two complexes FY26 and FY25.
Paper Metallomics
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
7 
Se
pt
em
be
r 2
01
9.
 D
ow
nl
oa
de
d 
on
 1
0/
14
/2
01
9 
4:
30
:5
6 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2019 Metallomics
Analysis (ChemStation version B.03.05, Agilent Technologies,
Inc.). The osmium content of cells was converted to intracellular
molar concentration assuming a single cell volume of 1 pL.18,19
See ESI,† for full numerical data.
Mathematical modeling
Mathematical models are based on ordinary diﬀerential equa-
tions computing the time evolution of intracellular and extra-
cellular FY25 and FY26 concentrations (see ESI,† for details). All
models include two physiological compartments corresponding
to the extracellular medium and the intracellular medium of one
million cells. The volume of the culture medium was set to 6 mL
and that of the intracellular compartment was estimated as 1 mL
assuming a single cell volume of 1 pL.18,19 Parameter estimation
consisted in a weighted least-square approach using the CMAES
algorithm for the minimization task. All individual data points
were fitted by iteratively running the estimation procedure and
updating initial conditions with the current best-fit parameters
until reaching convergence. Model identifiability was performed
using the profile likelihood method20 (see ESI†). Parameter 95%
confidence intervals were derived from the likelihood profiles.
All computations were carried out in Matlab (Mathworks, USA).
Results
FY25 and FY26 cellular transport
First, A2780 human ovarian cancer cells were treated with chlor-
ido complex FY25 or iodido complex FY26 for 72 h at physiolo-
gical temperature (37 1C) using equipotent IC50 concentrations in
this cell line (1.5 mM and 0.15 mM respectively). The intracellular
concentration of Os in treated cells was subsequently determined
using ICP-MS after acidic digestion of cell pellets. During exposure
to FY25, Os accumulated in A2780 cells in the course of the first
24 h. After that time, the intracellular Os concentration decreased
gradually for the next 48 h (Fig. 2A). Similarly, treatment of
ovarian cancer cells with FY26 resulted in an intracellular accu-
mulation of Os over the first 12 h and then an overall decrease in
Os concentration over the following 48 h of exposure. Intracellular
Os concentration versus time profiles are very similar for exposure
to either FY25 or FY26 (Fig. 2A).
To further investigate the cellular transport of FY25 and FY26,
the decrease in intracellular accumulation of Os was determined
after exposing the cells to these complexes for 24 h and then
replacing the culture medium with fresh complex-free culture
medium (so called ‘recovery time’ in complex-free medium).
During this experiment, cells were washed with PBS before
recovery time to ensure that the Os measured was indeed in
the intracellular space and not on the outer cellular surface of
the monolayer nor in the leftover medium in the well. After such
careful removal of either complex from the extracellular med-
ium, the intracellular concentration of Os decreased over the
duration of the experiment, with similar kinetics for either FY25
or FY26 exposure (Fig. 2B).
To assess whether energy-dependent mechanisms are involved
in the cellular transport of the complexes, ovarian cells were
exposed to FY25 or FY26 at 4 1C, 23 1C or 37 1C over 8 h. For all
of these time points, intracellular accumulation of Os increased
with temperature. After 8 h of exposure to either FY25 or FY26, the
Fig. 2 Cellular transport of FY25 (1.5 mM, blue) and FY26 (0.15 mM, red) in A2780 human ovarian cancer cells. (A) Intracellular osmium accumulation
during exposure to chlorido complex FY25 or iodido complex FY26 over 72 h. (B) Intracellular osmium concentration after a 24 h-exposure to FY25 or
FY26 followed by drug removal by replacement of the medium with drug-free medium. (C) Temperature-dependent intracellular osmium accumulation
during exposure to FY25 or FY26 over 8 h at 4, 23 and 37 1C. Datapoints for FY25 and FY26 exposure at 4 1C are superimposed.
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Os intracellular concentration decreased by 3.6 and 4-fold respec-
tively at 23 1C, and by 20.3 and 31.1 fold respectively at 4 1C,
compared to those determined at 37 1C (Fig. 2C).
Mathematical modeling of FY25 and FY26 cellular
pharmacokinetics
The designed models of the cellular pharmacokinetics (PK) of
FY25 and FY26 aimed to investigate quantitatively the cell
uptake and eﬄux of each complex together with the activation
of FY26 into FY25 (Fig. S1 in ESI†). The first accumulation study
without recovery time showed that Os intracellular concen-
tration decreased after 24 h of exposure to either complex
(Fig. 2). The hypothesis that FY26 and FY25 concentrations in
the culture medium decreased over time was ruled out since
(i) the complexes are stable in culture medium11 and (ii) the
extracellular volume (10 mL) was much greater than the total
intracellular volume of all cells (ca. 4 mL, calculated as 4 million
cells  1 pL each) so the quantity of Os accumulating in the
cells was negligible with respect to extracellular concentrations
of complexes. Thus, FY26 or FY25 were assumed not to dis-
appear spontaneously from the extracellular compartment. The
Os concentration versus time profiles which first increased and
then decreased towards zero values could not be accounted for
using a simple model incorporating linear uptake and eﬄux
terms with constant reaction rates which allowed only for
increasing profiles of Os intracellular concentration ultimately
reaching a non-zero steady state level. Thus, two mathematical
models were designed to investigate the intracellular mechan-
isms that might operate during exposure to complexes and
aﬀect their cellular transport. Such mechanisms could enable
cancer cells to evade damage caused by the metal complex, and
so, their molecular understanding might be important in
further preclinical studies. Two hypotheses were investigated:
the presence of either (i) enhanced eﬄux or (ii) reduced uptake,
both as a result of exposure to the organo-osmium complexes
(Fig. 3). The ‘‘enhanced eﬄux’’ model assumes that FY25
activates a Nuclear Factor (NF) that in turn enhances the
transcription of eﬄux transporters, hence increasing eﬄux of
the complex from the cells. Such assumptions rely on experi-
mental studies demonstrating that the expression of the ATP-
Binding Cassette transporters Abcb1 and Abcg2 is mediated by
nuclear factors NFkB and Nrf2, respectively.21 In contrast, the
‘‘reduced uptake’’ model assumes that the decrease in intra-
cellular Os accumulation results from the activation of an
unspecified chemical species that increases the degradation
of influx transporters leading to a decrease in cellular uptake of
the complex. For both models, complex-induced activation
leading to modified transport was assumed to occur when the
intracellular concentration of the complex reaches a critical
activation threshold.21 The models for FY25 exposure account
only for the uptake and eﬄux of the complex, and the activation
threshold depends on the intracellular concentration of FY25.
For modeling FY26 exposure, an additional step corresponding
to the transformation of FY26 into FY25 in the intracellular
compartment was included. The transport of both FY25 and
FY26 was included, and the activation threshold was assumed
to depend on the sum of FY25 and FY26 intracellular concen-
trations. Equations for the models and their associated para-
meters are presented in the ESI,† (Tables S1–S3).
Model fit to data provides molecular insights into cellular PK of
complexes
Parameters of either the ‘‘enhanced eﬄux’’ or the ‘‘reduced
uptake’’ models were fitted to the two available datasets for Os
accumulation experiments, with and without recovery time
(Fig. 4 and 5). The ‘‘enhanced eﬄux’’ model was not able to
reproduce both datasets at the same time, the best-fit model
achieving a poor fit for the experiment without recovery time and
a good fit for the experiment with recovery time. That result
suggested that this model did not correspond to a reasonable
molecular mechanism applicable to these experiments (Fig. 4).
In contrast, the ‘‘reduced uptake’’ model achieved a very good fit
to the data (Fig. 5). The model-to-data distance evaluated by the
Sum of Squared Residuals (SSR) was equal to 2826 for the
‘‘enhanced eﬄux’’ model and 291 for the ‘‘reduced uptake’’
model confirming the superiority of the second model (Table 1).
To further investigate the validity of the ‘‘reduced uptake’’
model, parameter practical identifiability was investigated
(see Methods and ESI,† Fig. S6). All model parameters were
identifiable except two parameters, which proved the reliability
of the model. The first parameter which was not identifiable
corresponded to the rate constant for conversion of FY26 into
FY25, whose optimal value was estimated as zero. However, this
was actually an artefact arising from the datasets used in the
estimation procedure as setting this parameter to zero made
the estimation of transport parameters for FY25 and FY26
independent. Next, the second parameter which was not iden-
tifiable was the Hill power, which set the steepness of the Hill
kinetics assumed for compound-induced uptake decrease. This
parameter was estimated to the highest investigated value, that
is 14, which corresponded to the highest steepness. However,
any value of this parameter above 10 achieved the optimal value
of the likelihood, hence the best fit to the data (Fig. 6).
In the ‘‘reduced uptake’’ model, the cellular transport rate
for FY26 was estimated to be faster than that of FY25, by 1.5-
fold for eﬄux and 17.7-fold for uptake (Table 1). This appears to
Fig. 3 Mathematical models of FY25 cellular pharmacokinetics consider-
ing either an enhanced eﬄux or a reduced uptake of the complex as a
result of its administration to A2780 cancer cells.
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correlate with the lower cytotoxicity of FY25 compared to that of
FY26,22 and structurally related ruthenium complexes,23 thus
providing a partial validation of the model. The activation
threshold corresponding to the intracellular osmium concen-
tration above which alteration in the rate of complex transport
was triggered was estimated as 20.8 mM (95% confidence
interval [16.5, 30]), and was reached 4 to 5 h after the start of
FY25 or FY26 exposure. After that time, the unknown species
was then activated in the mathematical model and enhanced
the degradation of uptake transporters with similar kinetics for
FY25 and FY26 exposure (Fig. 5E and F).
Next, we investigated whether these mathematical results
could depend on the choice of kinetics used in the mathema-
tical modelling to represent the PK of the complexes. Linear
kinetics of FY25 and FY26 transport and of FY26 activation
were changed to Michaelis–Menten terms. We observed that
Michaelis–Menten kinetics did not enable the ‘‘enhanced
efflux’’ model to fit the experimental data (SSR = 2650), but
still allowed for a very good fit of the ‘‘reduced uptake’’ model
(SSR = 291), thus indicating that the superiority of the second
model did not depend on the choice of kinetics. Altogether,
these results advocated decreased uptake of the complexes
rather than increased efflux as an explanation for the overall
decrease in osmium accumulation after 24 h of FY25 or FY26
exposure.
Temperature dependence of cellular transport parameters
We further investigated the temperature-dependence of Os
accumulation during the first 8 h of exposure. Intracellular
accumulation of Os in ovarian cancer cells exposed to either
FY25 or FY26 decreased as a function of temperature (Fig. 7).
The model developed above was used to analyse the tempera-
ture dependence of transport parameters. For the sake of
simplicity and in the absence of detailed data, the influence
of the complexes on their own cellular uptake was neglected as
the analysis above predicted that the transport of the com-
pounds was altered only after 4 to 5 hours of exposure. FY25
and FY26 uptake parameters were unchanged for the experi-
ment performed at 37 1C and were estimated from the osmium
accumulation datasets for experiments at 23 1C and 4 1C. All
other model parameters were assumed not to be aﬀected by
temperature. The model calibrated from the datasets of Fig. 4
and 5 achieved a good fit to this new dataset obtained at 37 1C
(Fig. 7). Furthermore, the model predicted that rate constants
for FY25 uptake at 23 1C and 4 1C were equal to 36% and 3.1%,
respectively, of those at 37 1C. Similarly, the rate constants of
Fig. 4 Poor data fit for the ‘‘enhanced eﬄux’’ model. No parameter set could be found to fit all datasets simultaneously. (A and B) experimental
intracellular osmium accumulation (dots) and model-predicted intracellular concentrations of FY25 (blue solid lines) and FY26 (red solid lines) in A2780
cancer cells treated with equipotent concentrations (1 IC50) of FY25 (A) or FY26 (B). (C and D) Intracellular osmium accumulation (dots) and model-
predicted intracellular concentrations of FY25 (blue solid lines) and FY26 (red solid lines) after 24 h exposure to FY25 (C) or FY26 (D), followed by 48 h
recovery time in complex-free culture medium.
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FY26 uptake at 23 1C and 4 1C were equal to 29% and 2.8%,
respectively, of those at 37 1C (Fig. 7).
Discussion
Knowledge of the kinetics of drug uptake, eﬄux and accumula-
tion in cancer cells is important for optimisation not only of drug
design, but also of treatment regimens, including the selection of
combination therapies. In general, our understanding of the
uptake and eﬄux mechanisms for metallodrugs is poor. The
most widely used drug in cancer chemotherapy is cisplatin and
even now, 40 years after its introduction into clinical use, its
transport mechanisms have not been fully elucidated.
Here we have studied the time- and temperature-dependent
accumulation of a promising iodido organo-osmium anticancer
drug candidate [(Z6-p-cymene)Os(Ph-azopyridine-NMe2)I]
+ (FY26)
by A2780 human ovarian cancer cells. This complex is inert and a
pro-drug which is activated inside cancer cells to form the more
reactive chlorido complex [(Z6-p-cymene)Os(Ph-azopyridine-
NMe2)Cl]
+ (FY25) as a major metabolite. Other species that are
likely to be formed include the hydroxido complex, the glu-
tathione adduct, and oxidised glutathione sulfenate adduct.14
The ability of chloride and hydroxide to bind strongly to Os(II)
even in the presence of a large molar excess of glutathione is
notable and contrasts with the behaviour of Pt(II) in cisplatin.
We have compared the time-dependent accumulation of the
chlorido complex FY25 and iodido complex FY26 in human
ovarian cancer cells and constructed models which account for
extent and time dependence of the influx and eﬄux of the
complexes and the intracellular conversion of FY26 into FY25.
The marked decrease in the accumulation of Os after 24 h of
exposure to the complexes is well described by mathematical
Fig. 5 Good data fit for the ‘‘reduced uptake’’ model: (A and B). Intracellular osmium accumulation (dots) and model-predicted concentrations of FY25
(blue solid lines) and FY26 (red solid lines) in A2780 cancer cells treated with equipotent concentrations (1 IC50) of FY25 (A) or FY26 (B) for 72 h. (C and D):
Intracellular osmium accumulation (dots) and model-predicted concentrations of FY25 (blue solid lines) and FY26 (red solid lines) after 24 h exposure to
equipotent concentrations of FY25 (C) or FY26 (D), followed by 48 h recovery time in complex-free medium. (E and F) Intracellular concentrations of the
complex-activated species (E) and of the uptake transporter (F) during exposure to either FY25 (blue) or FY26 (red) without recovery time (see Fig. 3).
Table 1 Best-fit parameter estimates for the ‘‘reduced uptake’’ model.
Confidence intervals were derived from the likelihood profiles study
Complex Estimate
95% Confidence
interval Units
FY25 active uptake 6.03 [5.3, 6.8] mM1 h1
FY25 active eﬄux 108.3 [103.5, 114.8] h1
FY26 active uptake 0.0265 [0.0254, 0.0274] mM1 h1
FY26 active eﬄux 0.0407 [0.039, 0.0425] h1
FY26 to FY25 transformation 0 [0, +N] h1
Activation threshold 20.8 [16.5, 30] mM
Activation hill power 14 [2.2, +N] —
Activation rate constant 0.86 [0.74, 1.18] h1
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modelling which reveals that this can be explained by complex-
induced decrease in osmium uptake, but not by enhanced
osmium eﬄux (Fig. 4 and 5). The validity of the ‘‘reduced
uptake’’ model was further strengthened by its accurate pre-
diction of the 17 faster uptake of FY26 at 37 1C and 1.4 faster
eﬄux of FY26 as compared to those of FY25, as demonstrated
in previous experiments which were not used for model design
nor calibration. Drug-induced uptake reduction could consti-
tute a defence mechanism to slow down the accumulation of
antiproliferative drugs into cancer cells, thus leading to a
decreased cytotoxicity.
This combined experimental and modelling result suggests
that specific active transporters are involved in the uptake of
these organo-osmium complexes. Indeed, there are reported
examples of transport proteins involved in the uptake and
eﬄux of metallodrugs. Early on it was thought that the main
route of cellular accumulation of cisplatin, present in extra-
cellular media as the neutral molecule cis-[PtCl2(NH3)2], relied
Fig. 6 Likelihood profiles for parameters of the ‘‘reduced uptake’’ model. Stars represent the optimal parameter value. Red lines are the 95% confidence
threshold value. If the likelihood profile crosses the threshold value twice (i.e. when increasing and decreasing parameter value starting from optimal
value), this proves parameter identifiability. The points at which the likelihood profile crosses the threshold are the ranges of the parameter 95%
confidence interval.
Fig. 7 Temperature-dependence of osmium accumulation in A2780 cancer cells treated with equipotent concentrations of FY25 or FY26. Solid lines
represent the best-fit of the model for FY25 (left) and FY26 (right) exposure at the stipulated temperatures.
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only on passive diﬀusion. However, more recent studies have
suggested that active transport, including specific membrane
proteins, might be also involved. These include the copper
transporters Ctr1 and Ctr2,24,25 although the relevance of these
to platinum treatment is currently in doubt.26 Alternatively, the
p-type copper transporters ATP7A and ATP7B have also been
linked to cisplatin resistance. However, the mechanism by
which copper transporters might transport cisplatin (or other
platinum drugs) is unclear. These proteins tend to be rich in
sulfur ligands (methionine and cysteine side chains), and the
strong trans eﬀect of sulfur can readily lead to trans-ligand
displacement from Pt(II). Organic cation transporters and
multidrug resistance transporters (e.g. MDR1, p-glycoprotein)
may also play a role in platinum transport and resistance.26 In
comparison, the arsenic drug, arsenic trioxide, is transported
into cells via aquaglyceroporin membrane transporters, per-
haps understandable due to its structure in solution, [As(OH)3],
which is a glycerol mimic.27
We can expect that the transporters used by metallodrugs
will depend intimately on the structures of the complexes,
including the metal and its oxidation state, the types and
number of bound ligands, and the coordination geometry.
Previously, we studied the A2780 cellular uptake and accumula-
tion of iminopyridine complexes of Ru(II) arene iminopyridine
complexes [Ru(Z6-p-cymene)(N,N-dimethyl-N0-[(E)-pyridine-2-
ylmethylidene]benzene-1,4-diamine)X]+ where X = Cl or I.
Remarkably, whereas the chlorido complex was taken up largely
by active transport, passive transport dominated for the iodido
complex. Cellular eﬄux of Ru was slow, and was partially inhibited
by the eﬄux pump inhibitor verapamil, which suggested a role for
P-glycoprotein in the eﬄux of the drug.23 Furthermore, for the
diamino arene Ru(II) complex [Ru(biphenyl)(ethylenediamine)Cl]+
which is cross-resistant with Adriamycin, drug resistance in A2780
cells was almost completely reversed by verapamil, suggesting that
this protein plays a major role in the eﬄux of the ruthenium
anticancer complex.28
Conclusions
Most metallodrugs are pro-drugs so understanding their transport
and activation becomes important for understanding their
mechanisms of action. Experimental work on the mechanisms
of action of metallodrugs is challenging since it requires determi-
nation of not only the metal and its oxidation state, but also the
nature of the bound ligands, both monodentate and chelated.
Here we are fortunate that osmium is not a biologically essential
metal, and thus its concentrations can be readily quantified using
ICP-MS at pharmacologically-relevant doses. Although both
cisplatin and the organo-osmium complexes studied here are
activated by exchange of monodentate ligands, the mechanisms
of exchange are quite diﬀerent. In the case of the azopyridine
complexes, it appears to involve attack on the azo bond of the
chelated ligand by intracellular glutathione (GSH).14,15 Moreover
the organo-osmium complexes appear to localise in the cytoplasm
of cancer cells,29 whereas cisplatin exerts its eﬀect in the nucleus.
This combined experimental and mathematical study
allowed us to identify a probable eﬀect of FY25 and FY26 on
their own cellular uptake leading to decreased intracellular
accumulation. Future work will involve investigations of possible
specific membrane transporter proteins for FY26. This complex
induces redox changes in cancer cells,10 especially the produc-
tion of reactive oxygen species (ROS). Whether this leads to
protein damage and loss of function of a transporter, or whether
attack on mRNA could be involved, requires further investiga-
tion. ROS-induced attack on intracellular proteins may be related
to the apparent block of osmium uptake after an intracellular
threshold osmium concentration has been reached. Further
work is required to investigate whether this is due to degradation
of a specific transporter protein or another mechanism. Such
considerations are important for the preclinical development of
FY26 and will aﬀect the choice of treatable cancers and the
choice of therapeutic combinations with other drugs.
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